Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function (NMN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03151239|
Recruitment Status : Recruiting
First Posted : May 12, 2017
Last Update Posted : August 3, 2017
|Condition or disease||Intervention/treatment|
|Glucose Metabolism Disorders||Dietary Supplement: NMN supplement Other: Placebo|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Effect of NMN (Nicotinomide Mononucleotide) Supplementation on Cardiometabolic Function|
|Actual Study Start Date :||July 1, 2017|
|Estimated Primary Completion Date :||June 1, 2019|
|Estimated Study Completion Date :||June 1, 2020|
|Placebo Comparator: Placebo||
Intervention will last 8 weeks in the form of two capsules.
|Experimental: NMN supplementation||
Dietary Supplement: NMN supplement
Intervention will last 8 weeks in the form of two capsules (250 mg total).
Other Name: nicotinamide mononucleotide
- To determine change in insulin sensitivity. [ Time Frame: 2 years ]This will be determined by observing liver and skeletal muscle insulin sensitivity (assessed by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope tracer infusion).
- To determine change in beta-cell function. [ Time Frame: 2 years ]This will be determined by looking at β-cell function (assessed by using the frequently sampled intravenous glucose tolerance test).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03151239
|Contact: Sally Torbitzky, BSNemail@example.com|
|Contact: Mihoko Yoshino, MDfirstname.lastname@example.org|
|United States, Missouri|
|Washington University School of Medicine||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Sally Torbitzky, RN, BSN 314-362-9950 email@example.com|
|Contact: Mihoko Yoshino, MD 314-362-8228 firstname.lastname@example.org|
|Principal Investigator: Samuel Klein, MD|
|Principal Investigator:||Samuel Klein, MD||Washington University School of Medicine|